Hindustan Antibiotics

This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources. Find sources: "Hindustan Antibiotics" – news · newspapers · books · scholar · JSTOR (December 2011)

Hindustan Antibiotics Limited

Company type	Central Public Sector Undertaking
Industry	Pharmaceuticals
Founded	10 March 1954
Headquarters	Pimpri, Pune, India
Key people	Mrs.Neerja saraf(MD & CEO)
Products	Antibiotics like Penicillin Streptomycin Gentamicin Amoxycillin
Revenue	USD 12 million (FY)
Owner	Ministry of Chemicals and Fertilizers, Government of India
Number of employees	1,500
Website	www.hindantibiotics.in

Hindustan Antibiotics Limited (HAtL) is an Indian central public sector undertaking under the ownership of Ministry of Chemicals and Fertilizers, Government of India. It is based in Pune, India. It is the first government-owned-drug manufacturer in India. It was the first to launch a recombinant DNA product, rHU-Erythropoietin (Hemax) in 1993.

It introduced new products like Halpen, Haltax, Hexpan in 2008. Sati-HIV drugs will be produced from September 2009.^[1]

History

HAtL was set up in cooperation with the WHO and UNICEF with the social objective of providing affordable drugs throughout India. It was inaugurated by India's first Prime Minister Jawaharlal Nehru on 10 March 1954. Production began in 1955. It was based on Mahatma Gandhi's vision that the poor in India should get medicines at affordable rates.

After reporting an operating loss in 1997 the company was reported to the Bureau of Industrial and Financial Restructuring (BIFR). On 17 January 2009 the company was taken off the books of the BIFR after reporting a record turnover of ₹ 120 crore (US$24 million).

Operations

Although the company's primary objective was to develop drugs for the health-care industry, the company has now diversified into the agricultural and veterinary areas as well. The manufacturing plant located in Pimpri has facilities to produce bulk drugs (capacity 60 MMU annually) as well as formulations in various dosage forms – injectables (132 million vials), capsules (250 million), tablets (120 million), large volume parentrals^{[clarification needed]} (12 million bottles annually), liquid orals, etc.

In-house developed products

Health care

• Hamycin (own research product)
• Ampicillin Sodium
• Benzyl Penicillin Potassium
• Benzyl Penicillin Sodium
• Benzathine Penicillin (Longacillin)
• Cefuroxime Sodium
• Amoxycillin Trihydrate (Delamin)
• Cefotaxime Sodium (Haltax)
• Ceftriaxone Sodium (Haxone)
• Meropenem (Halpen)

Agricultural and veterinary

• Aureofungin (anti-fungal used in preservation of the fruits and vegetables)
• Humaur (bio-organic foliar spray)
• Streptocycline (antibacterial for effective control of diseases in plants)
• Azotomeal
• Phosphomeal

References

External links

• Official website